Skip to main content
Top
Published in: Calcified Tissue International 1/2005

01-01-2005

Relationships Between the Changes of Serum Levels of OPG and RANKL with Age, Menopause, Bone Biochemical Markers and Bone Mineral Density in Chinese Women Aged 20-75

Authors: J. M. Liu, H. Y. Zhao, G. Ning, Y. J. Zhao, Y. Chen, Zh. Zhang, L. H. Sun, M.-Y. Xu, J. L. Chen

Published in: Calcified Tissue International | Issue 1/2005

Login to get access

Abstract

The correlations between the serum levels of OPG, RANKL with age, menopause, bone markers, and bone mineral densities (BMDs) at the lumbar spine and proximal femur were studied in 504 pre- and postmenopausal Chinese women aged 20–75 years. We found that age was positively and negatively correlated with serum concentrations of OPG (r = 0.442, P < 0.001) and RANKL (r = −0.263, P < 0.001), respectively. Compared with premenopausal women, postmenopausal women showed higher serum OPG levels (107.6 ± 3.0 vs 72.0 ± 1.8 pg/ml, P < 0.001), lower serum RANKL concentrations (4.7 ± 0.4 vs. 5.8 ± 0.3 pg/ml, P < 0.001) and RANKL/OPG ratios (0.045 ± 0. 004 vs. 0.099 ± 0.008, P < 0.001). Neither serum levels of OPG nor RANKL or RANKL/OPG ratio correlated with BMDs after adjustment of age and menopause. They also showed no differences among normal, osteopenic and osteoporotic postmenopausal women. Serum levels of OPG were positively correlated with urinary excretion of NTx (r = 0.1453, P = 0.006). Serum levels of RANKL (r = −0.1928, P < 0.001) and RANKL/OPG ratio (r = −0.1303, P = 0.013) were inversely correlated with serum concentrations of OC. In multiple regression analysis, up to 20% variance (R2 = 0.106–0.224) of the OPG-RANKL system in peripheral circulation can be explained by age, menopause and bone markers.
These results suggest that although serum OPG and RANKL concentrations were unrelated with BMDs, the age– and menopause– dependent changes of serum OPG and RANKL might be a protective mechanism against the accelerated bone loss in postmenopausal women.
Literature
2.
go back to reference Lacey, DL, Timms, E, Tan, HL 1998Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell93165176CrossRefPubMed Lacey, DL, Timms, E, Tan, HL 1998Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell93165176CrossRefPubMed
3.
go back to reference Kostenuik, PJ, Shalhoub, V 2001Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorptionCurr Pharm Res7613635 Kostenuik, PJ, Shalhoub, V 2001Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorptionCurr Pharm Res7613635
4.
go back to reference Simonet, WS, Lacey, DL, Dunstan, CR 1997Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell89309319CrossRefPubMed Simonet, WS, Lacey, DL, Dunstan, CR 1997Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell89309319CrossRefPubMed
5.
go back to reference Mizuno, A, Amizuka, N, Irie, K 1998Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerinBiochem Biophys Res Commun247610615CrossRefPubMed Mizuno, A, Amizuka, N, Irie, K 1998Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerinBiochem Biophys Res Commun247610615CrossRefPubMed
6.
go back to reference Whyte, MP, Obrecht, SE, Finnegan, PM 2002Osteoprotegerin deficiency and juvenile Paget’s diseaseN Engl J Med347175184CrossRefPubMed Whyte, MP, Obrecht, SE, Finnegan, PM 2002Osteoprotegerin deficiency and juvenile Paget’s diseaseN Engl J Med347175184CrossRefPubMed
7.
go back to reference Kong, YY, Yoshida, H, Sarosi, I 1998OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature397315323 Kong, YY, Yoshida, H, Sarosi, I 1998OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature397315323
8.
go back to reference Capparelli, C, Morony, S, Warmington, K 2003Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in ratsJ Bone Miner Res18852858PubMed Capparelli, C, Morony, S, Warmington, K 2003Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in ratsJ Bone Miner Res18852858PubMed
9.
go back to reference Bekker, PJ, Holloway, D, Nakanishi, A 2001The effect of a single dose of osteoprotegerin in postmenopausal womenJ Bone Miner Res16348360PubMed Bekker, PJ, Holloway, D, Nakanishi, A 2001The effect of a single dose of osteoprotegerin in postmenopausal womenJ Bone Miner Res16348360PubMed
10.
go back to reference Buckley, KA, Fraser, WD 2002Receptor activator for nuclear factor kappa B ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markersAnn Clin Biochem39551556CrossRefPubMed Buckley, KA, Fraser, WD 2002Receptor activator for nuclear factor kappa B ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markersAnn Clin Biochem39551556CrossRefPubMed
11.
go back to reference Rogers, A, Saleh, G, Hannon, RA 2002Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal womenJ Clin Endocrinol Metab8744704475CrossRefPubMed Rogers, A, Saleh, G, Hannon, RA 2002Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal womenJ Clin Endocrinol Metab8744704475CrossRefPubMed
12.
go back to reference Kudlacek, S, Schneider, B, Woloszczuk, W 2003Serum levels of osteoprotegerin increase with age in a healthy adult populationBone32681686CrossRefPubMed Kudlacek, S, Schneider, B, Woloszczuk, W 2003Serum levels of osteoprotegerin increase with age in a healthy adult populationBone32681686CrossRefPubMed
13.
go back to reference Terpos, E, Szydlo, R, Apperley, JF 2003Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicted survival in multiple myeloma. Proposal for a novel prognostic indexBlood10210641069CrossRefPubMed Terpos, E, Szydlo, R, Apperley, JF 2003Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicted survival in multiple myeloma. Proposal for a novel prognostic indexBlood10210641069CrossRefPubMed
14.
go back to reference Alvarez, L, Peris, P, Guanabens, N, Vidal, S, Res, I, Pons, F, Filella, X, Monegal, A, Munoz-Gomes, J, Ballesta, AM 2003Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonatesArthritis Rheum48824828CrossRefPubMed Alvarez, L, Peris, P, Guanabens, N, Vidal, S, Res, I, Pons, F, Filella, X, Monegal, A, Munoz-Gomes, J, Ballesta, AM 2003Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonatesArthritis Rheum48824828CrossRefPubMed
15.
go back to reference Ziolkowska, M, Kurowska, M, Radzikowska, A 2002High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatmentArthritis Rheuma,4617441753 Ziolkowska, M, Kurowska, M, Radzikowska, A 2002High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatmentArthritis Rheuma,4617441753
16.
go back to reference Liu, JM, Zhao, HY, Ning Guang, 2004Relationship between body composition and bone mineral density in healthy young and premenopausal Chinese womenOsteoporos Int15238242CrossRefPubMed Liu, JM, Zhao, HY, Ning Guang,  2004Relationship between body composition and bone mineral density in healthy young and premenopausal Chinese womenOsteoporos Int15238242CrossRefPubMed
17.
go back to reference WHO Scientific Group Research on the menopause in the 1990’s (1996) A report of the WHO Scientific Group. World Health Organization, Geneva, Switzerland. 866:1–79 WHO Scientific Group Research on the menopause in the 1990’s (1996) A report of the WHO Scientific Group. World Health Organization, Geneva, Switzerland. 866:1–79
18.
go back to reference WHO Assessment of fracture risk, its application to screening for postmenopausal osteoporosis (1994) Report of a WHO study Group. WHO Technical Report Series, No. 843 WHO Assessment of fracture risk, its application to screening for postmenopausal osteoporosis (1994) Report of a WHO study Group. WHO Technical Report Series, No. 843
19.
go back to reference Yano, K, Tsuda, E, Washida, N 1999Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibiting factor: increased serum concentrations in postmenopausal women with osteoporosisJ Bone Miner Res14518527PubMed Yano, K, Tsuda, E, Washida, N 1999Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibiting factor: increased serum concentrations in postmenopausal women with osteoporosisJ Bone Miner Res14518527PubMed
20.
go back to reference Fahrleitner-Pammer, A, Dobnig, H, Piswanger-Soelkner, C 2003Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture statusWien Klin Wochenschr115291297PubMed Fahrleitner-Pammer, A, Dobnig, H, Piswanger-Soelkner, C 2003Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture statusWien Klin Wochenschr115291297PubMed
21.
go back to reference Junk, K, Lein, M, Hosslin, K 2002Osteoprotegerin and receptor activator of nuclear factor-Kappa B ligand (RANKL) in the serum of healthy adultsInt J Biol Markers17177181PubMed Junk, K, Lein, M, Hosslin, K 2002Osteoprotegerin and receptor activator of nuclear factor-Kappa B ligand (RANKL) in the serum of healthy adultsInt J Biol Markers17177181PubMed
22.
go back to reference Eghbali-Fatourechi, G, Khosla, S, Sanyal, A 2003Role of RANK ligand in mediating increased bone resorption in early postmenopausal womenJ Clin Invest11812211230CrossRef Eghbali-Fatourechi, G, Khosla, S, Sanyal, A 2003Role of RANK ligand in mediating increased bone resorption in early postmenopausal womenJ Clin Invest11812211230CrossRef
23.
go back to reference Browner, WS, Lui, LY, Cummings, SR 2001Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly womenJ Clin Endocrinol Metab86631637CrossRefPubMed Browner, WS, Lui, LY, Cummings, SR 2001Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly womenJ Clin Endocrinol Metab86631637CrossRefPubMed
24.
go back to reference Khosla, S, Aggighi, HM, Melton, LJ 2002Correlates of osteoprotegerin levels in women and menOsteoporos Int13394399CrossRefPubMed Khosla, S, Aggighi, HM, Melton, LJ 2002Correlates of osteoprotegerin levels in women and menOsteoporos Int13394399CrossRefPubMed
25.
go back to reference Yano, K, Shibata, O, Mizuno, A 2001Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancyBiochem Biophys Res Commun288217224CrossRefPubMed Yano, K, Shibata, O, Mizuno, A 2001Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancyBiochem Biophys Res Commun288217224CrossRefPubMed
26.
go back to reference Resch, H, Pietschmann, P, Kudlacek, S 1994Influence of sex and age on biochemical bone metabolism parametersMiner Electrolyte Metab20117121PubMed Resch, H, Pietschmann, P, Kudlacek, S 1994Influence of sex and age on biochemical bone metabolism parametersMiner Electrolyte Metab20117121PubMed
27.
go back to reference Ebeling, PR, Atley, LM, Guthrie, JR 1996Bone turnover markers and bone density across the menopausal transitionJ Clin Endocrinol Metab8133663371CrossRefPubMed Ebeling, PR, Atley, LM, Guthrie, JR 1996Bone turnover markers and bone density across the menopausal transitionJ Clin Endocrinol Metab8133663371CrossRefPubMed
28.
go back to reference Kakonen, SM, Hellman, J, Karp, M 2000Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serumClin Chem46332337PubMed Kakonen, SM, Hellman, J, Karp, M 2000Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serumClin Chem46332337PubMed
29.
go back to reference Pietschmann, P, Resch, H, Krexner, E 1991Decreased serum osteocalcin levels in patients with postmenopausal osteoporosisActa Med Austriaca18114116PubMed Pietschmann, P, Resch, H, Krexner, E 1991Decreased serum osteocalcin levels in patients with postmenopausal osteoporosisActa Med Austriaca18114116PubMed
30.
go back to reference Akesson, K, Ljunghall, S, Jonsson, B 1995Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of womenJ Bone Miner Res1018231829PubMed Akesson, K, Ljunghall, S, Jonsson, B 1995Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of womenJ Bone Miner Res1018231829PubMed
31.
go back to reference Power, MJ, Fottrell, PR 1991Osteocalcin. Diagnostic methods and clinical applicationCrit Rev Clin Lab Sci.28287335PubMed Power, MJ, Fottrell, PR 1991Osteocalcin. Diagnostic methods and clinical applicationCrit Rev Clin Lab Sci.28287335PubMed
32.
go back to reference Delmas, PD, Eastell, R, Garneo, P, Seibel, MJ, Stepan, J 2000The use of biochemical markers of bone turnover in osteoporosisOsteoporos Int 11 (Suppl 6)S217 Delmas, PD, Eastell, R, Garneo, P, Seibel, MJ, Stepan, J 2000The use of biochemical markers of bone turnover in osteoporosisOsteoporos Int 11 (Suppl 6)S217
33.
go back to reference Ivaska, KK, Hentunen, TA, Vaaraniemi, J 2004Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitroJ Biol Chem2791836118369 Ivaska, KK, Hentunen, TA, Vaaraniemi, J 2004Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitroJ Biol Chem2791836118369
34.
go back to reference Ber, CE, Kroner, A, Thomas, E 2002Comparison of biochemical markers of bone metabolism in serum and femur aspiratesClin Orthop395174179PubMed Ber, CE, Kroner, A, Thomas, E 2002Comparison of biochemical markers of bone metabolism in serum and femur aspiratesClin Orthop395174179PubMed
35.
go back to reference Dieo, ED, Martin, MA, Piedra, C 1995Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic womenHorm Metab Res27151154 Dieo, ED, Martin, MA, Piedra, C 1995Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic womenHorm Metab Res27151154
36.
go back to reference Lum, L, Wong, BR, Josien, R 1999Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survivalJ Biol Chem2741361313618 Lum, L, Wong, BR, Josien, R 1999Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survivalJ Biol Chem2741361313618
37.
go back to reference Nakashima, T, Kobayashi, Y, Yamasaki, S 2000Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokinesBiochem Biophys Res Commun.275768775CrossRefPubMed Nakashima, T, Kobayashi, Y, Yamasaki, S 2000Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokinesBiochem Biophys Res Commun.275768775CrossRefPubMed
38.
go back to reference Hofbauer, LC, Schoppet Osteoprotegerin, M. 2001A link between osteoporosis and arterial calcification?Lancet358257259CrossRefPubMed Hofbauer, LC, Schoppet Osteoprotegerin, M. 2001A link between osteoporosis and arterial calcification?Lancet358257259CrossRefPubMed
39.
go back to reference Knudsen, ST, Foss, CH, Poulsen, PL 2003Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complicationsEur J Endocrinol1493942PubMed Knudsen, ST, Foss, CH, Poulsen, PL 2003Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complicationsEur J Endocrinol1493942PubMed
40.
go back to reference Makhluf, HA, Mueller, SM, Mizuno, S 2000Age related decline in osteoprotegerin expression by human bone marrow cell cultured in three-dimensional collagen spongesBiochem Biophys Res Commun268669672CrossRefPubMed Makhluf, HA, Mueller, SM, Mizuno, S 2000Age related decline in osteoprotegerin expression by human bone marrow cell cultured in three-dimensional collagen spongesBiochem Biophys Res Commun268669672CrossRefPubMed
41.
go back to reference Cao, J, Venton, L, Sakata, T 2003Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 miceJ Bone Miner Res18270277PubMed Cao, J, Venton, L, Sakata, T 2003Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 miceJ Bone Miner Res18270277PubMed
Metadata
Title
Relationships Between the Changes of Serum Levels of OPG and RANKL with Age, Menopause, Bone Biochemical Markers and Bone Mineral Density in Chinese Women Aged 20-75
Authors
J. M. Liu
H. Y. Zhao
G. Ning
Y. J. Zhao
Y. Chen
Zh. Zhang
L. H. Sun
M.-Y. Xu
J. L. Chen
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2005
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-004-0007-2

Other articles of this Issue 1/2005

Calcified Tissue International 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.